Blair William & Co. IL Sells 7,509 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Blair William & Co. IL reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 6.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,400 shares of the company's stock after selling 7,509 shares during the period. Blair William & Co. IL owned approximately 0.13% of CRISPR Therapeutics worth $4,503,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP grew its holdings in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management raised its stake in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after purchasing an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $80,000. Institutional investors own 69.20% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CRSP shares. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a research report on Wednesday, February 12th. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Royal Bank of Canada cut their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Citigroup decreased their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Finally, The Goldman Sachs Group cut their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $73.11.

Remove Ads

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $32.65. The stock had a trading volume of 3,076,063 shares, compared to its average volume of 1,578,570. The company has a fifty day simple moving average of $42.15 and a 200-day simple moving average of $44.71. CRISPR Therapeutics AG has a 52 week low of $30.20 and a 52 week high of $67.88. The stock has a market cap of $2.80 billion, a PE ratio of -7.47 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.